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SignalingThe melanocortin-4 receptor (MC4R) is a G protein-coupled receptor critically involved in regulating energy
balance. MC4R activation results in decreased food intake and increased energy expenditure. Genetic and
pharmacological studies demonstrated that the MC4R regulation of energy balance is conserved from ﬁsh to
mammals. In humans, more than 150 naturally occurring mutations in the MC4R gene have been identiﬁed.
Functional study of mutant MC4Rs is an important component in proving the causal link between MC4R
mutation and obesity as well as the basis of personalized medicine. In this article, we studied 20 MC4R
mutations that were either not characterized or not fully characterized. We showed that 11 mutants had
decreased or absent cell surface expression. D126Y was defective in ligand binding. Three mutants were
constitutively active but had decreased cell surface expression. Eleven mutants had decreased basal signaling,
with two mutants defective only in this parameter, suggesting that impaired basal signaling might also be a
cause of obesity. Five mutants had normal functions. In summary, we provided detailed functional data for
further studies on identifying therapeutic approaches for personalized medicine to treat patients harboring
these mutations., G protein-coupled receptor;
4 receptor; MSH, melanocyte
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The melanocortin receptors are members of Family A G protein-
coupled receptors (GPCRs) involved in regulating diverse functions,
including pigmentation, adrenal steroid secretion, immune modulation,
energy homeostasis, exocrine gland secretion, pain perception, among
others. The ligands for these receptors are small peptides derived from
post-translational processing of pro-opiomelanocortin, including adre-
nocorticotropin andα-melanocyte stimulatinghormone(MSH),β-MSH,
and γ-MSH, as well as several other peptides [1,2]. These receptors are
unique among GPCRs in having endogenous antagonists, agouti and
agouti-related protein (AgRP). Agouti is the antagonist for the
melanocortin-1 receptor whereas AgRP is the endogenous antagonists
of themelanocortin-3 and -4 receptors (MC3R andMC4R, respectively).
TheMC4R iswidely expressed in the central nervous system, including
the hypothalamus [3]. It is a critical regulator of energy homeostasis.
MC4R activation leads to decreased food intake and increased energy
expenditure. When the MC4R is inactivated through gene targeting, theknockout mice have severe obesity, together with hyperglycemia and
hyperinsulinemia [4]. Mice lacking proopiomelanocortin gene [5] or over-
expressing AgRP [6,7] are obese. Pharmacological studies conﬁrmed the
critical role ofMC4R in regulating energy homeostasis (reviewed in [2,8]).
Following these rodent studies, human genetic studies conﬁrmed
that theMC4R is also indispensable for human energy homeostasis. Two
groups independently identiﬁed frameshift mutations in the MC4R in
patients with early-onset severe obesity in 1998 [9,10]. It is now well
accepted that mutations in the MC4R gene are the most common
monogenic form of obesity [11], withmore than 150 distinct mutations
identiﬁed so far [2,12].
Extensive functional studies were performed on some of these
mutations (reviewed in [2,12]). These studies were important in
establishing whether a particular mutation is indeed pathogenic. It was
suggested that three lines of evidences, including cosegregation in
pedigrees, absence in nonobese controls of the same ethnicity, and
impairment in receptor function, are needed to conclude that a particular
MC4R mutation is causative of obesity [13]. These studies identiﬁed
multiple functional defects. Based on these results, we proposed a
classiﬁcation scheme [14,15] as follows: Class I mutants are null mutants
with diminished receptor proteins; Class II mutants are retained
intracellularly; Class III mutants are defective in ligand binding; Class IV
mutants are defective in signaling; and ﬁnally, Class V mutants have
normal function in the parameters measured.
In the current study, we performed detailed functional studies on
18MC4Rmutations reported recently, including I69R [16], H76R [17],
1191Z.-Q. Wang, Y.-X. Tao / Biochimica et Biophysica Acta 1812 (2011) 1190–1199M79I [16], S94N [17], D126Y [17], D146N [17], Del170 [17], I186V [18],
I195S [16], F201L [17], G231V [17], P260Q [17], F280L [18], I289L [17],
R305S [17], Q307X [17], Y332C [17], and Y332H [17]. They were either
not characterized or characterized incompletely. I194T and L300P were
identiﬁed in mouse obesity models [19] and introduced into human
MC4R in the current study for comparison. These mutations are shown
schematically in Fig. 1.
2. Materials and methods
2.1. Hormones and supplies
[125I]-NDP-MSH ([Nle4,D-Phe7]-α-melanocyte stimulating hor-
mone) was obtained from the Peptide Radioiodination Service Center at
the University ofMississippi (University,MS) or American Radiolabeled
Chemicals (St. Louis, MO) iodinated by Dr. Robert C. Speth. α-MSH and
β-MSH were synthesized by Pi Proteomics (Huntsville, AL) and CHI
Scientiﬁc (Maynard, MA), respectively, and NDP-MSH was purchased
from Peptides International (Louisville, KY). Tissue culture plasticwares
and cell culturemedia, newborn calf serum, and reagentswere obtained
from Corning (Corning, NY) and Invitrogen (Carlsbad, CA), respectively.
2.2. In vitro mutagenesis of MC4R
Wild type (WT) human (h) MC4R (generously provided by Dr. Ira
Gantz) tagged at the N-terminus with c-myc epitope tag was described
previously [14]. Mutations were introduced into myc-hMC4R by
QuikChange™ site-directed mutagenesis kit (Stratagene, La Jolla, CA)
[14]. Plasmids used for transfection were prepared using IsoPure Maxi
Prep kit (Denville Scientiﬁc,Metuchen,NJ). AutomatedDNA sequencing
was used to verify that the full coding region was correct.
2.3. Cells and transfections
HEK293T cells, obtained from American Type Culture Collection
(Manassas, VA), were maintained at 5% CO2 in Dulbecco's modiﬁed
Eagle's medium containing 10 mM HEPES, 10% newborn calf serum,
100 units/ml penicillin and 100 mg/ml streptomycin. Cells wereFig. 1. Schematicmodel of the hMC4Rwith the mutations studied in this study highlighted wit
mutations corresponding to I194T and L300P were identiﬁed in obese mouse lines. The c-mycplated on gelatin-coated 35 mm 6-well clusters. Cells were trans-
fected using the calcium precipitation method [20]. One μg of
plasmids in 2 ml media was used per 35 mm dish. Cells were used
approximately 48 h after transfection for measuring ligand binding
and signaling. For confocal microscopy and ﬂow cytometry, stable
nonclonal cells were established after transfection of HEK293 cells
and selection with G418 as described previously [14,21].
2.4. Ligand binding to intact cells
The methods for ligand binding have been described in detail before
[14]. Brieﬂy, 48 h after transfection, cells were washed twice with warm
Waymouth/BSA (Waymouth's MB752/1 media, Sigma-Aldrich Cat #
W1625, containing 1 mg/ml bovine serumalbumin (BSA)) and incubated
with 100,000 cpm of 125I-NDP-MSH with or without different concen-
trations of unlabeled α- or β-MSH (from 10−10 to 10−5 M) at 37 °C for
1 h. Cellswere then placed directly on ice, washed twicewith coldHank's
balanced salt solution containing 1 mg/ml BSA. Then 100 μl of 0.5 M
NaOH was added to each well. Cell lysates were then collected using
cotton swabs, and counted in a gamma counter. Apparent maximal
binding (Bmax) [22] and IC50 values were calculated using Prism 4.0
software (San Diego, CA).
2.5. Ligand stimulation of intracellular cAMP production
HEK293T cells were plated and transfected as described above.
Approximately 48 h after transfection, cells were washed twice with
warm Waymouth/BSA. Then 1 ml of fresh Waymouth/BSA containing
0.5 mM isobutylmethylxanthine (Sigma-Aldrich, St. Louis, MO) was
added to each well. After 15 min incubation at 37 °C, either buffer alone
or different concentrations of α- or β-MSH were added and the
incubation was continued for another hour. Intracellular cAMP was
extracted by the addition of 0.5 N percholoric acid containing 180 μg/ml
theophylline (to inhibit phosphodiesterase activity), andmeasured using
radioimmunoassay [23]. All determinations were performed in triplicate.
Maximal response (Rmax) andEC50 valueswere calculatedusing Prism4.0
software.h gray background. All are naturally occurringmutations identiﬁed in humans except that
epitope at the N terminus is highlighted with white letters on a dark background.
Fig. 2. Ligand binding and signaling properties of the WT and mutant hMC4Rs with α-MSH as the ligand. HEK293T cells were transiently transfected with the indicated hMC4R
constructs and binding and signaling properties of the MC4Rs were measured as described inMaterials andmethods. In A, different concentrations of unlabeledα-MSHwere used to
displace the binding of 125I-NDP-MSH to hMC4Rs on intact cells. Results shown are expressed as % ofWT binding±range from duplicate determinations within one experiment. In B,
HEK293T cells transiently transfected with the indicated hMC4R constructs were stimulated with different concentrations ofα-MSH. Intracellular cAMP levels were measured using
RIA. Results are expressed as the mean±SEM of triplicate determinations within one experiment. All experiments were performed three times.
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The methods for confocal microscopy have been described in detail
before [14,21]. Brieﬂy, cells stably expressing MC4Rs were plated onto
lysine-coated slides (Biocoat cellware fromFalcon, BDSystems, Franklin
Lakes, NJ) and used for immunostaining 24 h later. All solutions and
procedures for immunohistochemistrywere at room temperature. Cells
were washed three times with ﬁltered phosphate buffered saline for
immunohistochemistry (PBS-IH, 137 mM NaCl, 2.7 mM KCl, 1.4 mM
KH2PO4, 4.3 mM Na2HPO4, pH 7.4). Cells were then ﬁxed with 4%
paraformaldehyde in PBS-IH for 30 min. Then the cells were incubated
with blocking solution (5% BSA in PBS-IH) for 1 h, and incubated 1 h
with monoclonal anti-myc (9E10) antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) diluted 1:100 in PBS-IH containing 1 mg/ml BSA. Cells
were then washed three times and incubated with Alexa Fluor 488-
conjugated goat anti-mouse IgG (Invitrogen) diluted 1:1000 in PBS-IH
containing 1 mg/ml BSA. Cells were then washed 5 times with PBS-IH
and covered with Vectashield Mounting Media (Vector Laboratories)
and a glass coverslip. Images were collected with a Bio-Rad laser
scanning confocalmicroscope. Alexa Fluor 488was excited by a 488-nm
argon laser and detected with a 530–560 nm ﬁlter.2.7. Flow cytometry assay to quantitate expression levels of mutant
MC4Rs
This assay was performed as described in detail before [24,25] except
that the antibodies used and dilutions of antibodies were the same as
described above for confocal microscopy. Fluorescence signals were
collectedwith a C6 Accuri Cytometer (Accuri Cytometers, Inc., Ann Arbor,
MI). All the steps were performed at room temperature. Fluorescence
from cells stably transfected with the empty vector was used to measure
background staining. The expression level of the mutants was calculated
as a percentage of WT MC4R expression using the formula: [mutant
ﬂuorescence−pcDNA3 ﬂuorescence]/[WT ﬂuorescence−pcDNA3
ﬂuorescence]×100%.Table 1
α-MSH-stimulated signaling and ligand binding of WT and mutant hMC4Rs.
hMC4R n α-MSH binding
IC50 (nM) B
WT 12 1684.23±412.59 1
I69R 3 NDa N
H76R 3 41.31±18.97b 1
M79I 3 328.30±75.53 9
S94N 3 53.70±11.70b 5
D126Y 3 NDa N
D146N 3 4.41±1.06b 5
Del170 3 NDa N
I186V 3 1084.70±75.18 9
I194T 3 NDa N
I195S 3 329.08±105.12b 1
F201L 3 1224.10±415.47 7
G231V 3 745.70±35.64 1
P260Q 3 NDa N
F280L 3 150.10±15.10b 8
I289L 3 1866.33±54.87 1
L300P 3 53.60±0.73b 6
R305S 3 2263.67±503.38 1
Q307X 3 NDa N
Y332C 3 957.03±398.64 1
Y332H 3 1674.37±552.71 1
The data are expressed as themean±SEM of three independent experiments for themutant
WT hMC4R.
a ND, could not be detected.
b Signiﬁcantly different from corresponding WT receptor, pb0.05.
c Signiﬁcantly different from corresponding WT receptor, pb0.01.
d Signiﬁcantly different from corresponding WT receptor, pb0.001.2.8. Statistic analyses
Ligand binding and signaling data were analyzed using GraphPad
Prism 4.0 to calculate IC50, EC50, Bmax, and Rmax. The signiﬁcance of
differences in cell surface expression levels and signaling and binding
parameters between the WT and mutant hMC4Rs were analyzed
using Student's t-test with Prism 4.0.
3. Results
3.1. Ligand binding and signaling to α-MSH
The endogenous ligand, α-MSH, is the most commonly used ligand
in MC4R studies. We therefore ﬁrst studied the binding and signaling
properties of the mutant receptors using α-MSH as the ligand. For
binding studies, iodinatedNDP-MSHwasusedbecauseα-MSH loses the
ability to bind to receptors after iodination. HEK293T cells transiently
transfectedwithWTormutant receptorswere incubatedwith iodinated
NDP-MSH in the absence or presence of increasing concentrations of
unlabeled α-MSH. After incubation, cells were washed and iodinated
NDP-MSH bound to the cell surface was measured. These experiments
showed that unlabeled α-MSH displaced the radiolabeled NDP-MSH
bound to theWTMC4Rwith an IC50 of 1684.23 nM(Fig. 2A andTable 1).
Of the twenty mutants, I69R, D126Y, Del170, I194T, P260Q, and Q307X,
had no measurable binding. S94N, D146N, and L300P had decreased
maximal binding. Severalmutants, includingH76R, S94N,D146N, I195S,
F280L, and L300P, had lower IC50s (increased afﬁnities).
When cells transfected with WT or mutant MC4Rs were stimulated
with α-MSH, WT MC4R responded with dose-dependent increases in
intracellular cAMP levels, with an EC50 of 2.59 nM (Fig. 2B and Table 1).
Six mutants, I69R, D126Y, Del170, I194T, P260Q, and Q307X, had no
response toα-MSH stimulation, consistent with their lack of detectable
binding. M79I, despite normal ligand binding, had decreased maximal
response and increased EC50 suggesting that this mutant was partially
defective in signaling. The other mutants could signal at least as well as
WT MC4R in terms of maximal signaling. R305S even had signiﬁcantlyα-MSH-stimulated cAMP
max (% wt) EC50 (nM) Rmax (% wt)
00 2.59±0.30 100
Da NDa NDa
51.05±4.21c 0.92±0.38 158.55±39.78
7.20±15.39 153.10±14.83d 59.84±2.99c
3.35±8.96b 5.26±0.66 218.48±44.69
Da NDa NDa
2.76±12.65 0.08±0.01c 133.47±31.68
Da NDa NDa
3.25±17.13 0.60±0.21 107.15±28.47
Da NDa NDa
13.43±14.23 3.11±0.82 282.55±66.91
8.64±7.53 8.41±0.09c 108.88±2.11
47.07±15.51 1.74±0.44 149.08±14.00
Da NDa NDa
2.50±18.20 0.64±0.15 174.40±33.59
18.41±12.34 0.55±0.17b 91.09±12.82
3.75±11.93 3.30±1.34 204.16±37.75
33.66±20.88 8.75±1.07c 180.56±5.59c
Da NDa NDa
63.97±14.75 0.34±0.07b 106.07±3.14
69.06±24.09 0.76±0.21b 129.92±26.91
hMC4Rs. Themaximal responses (Rmax) were 2572.42±281.39 pmol cAMP/106 cells for
Fig. 3. Ligand binding and signaling properties of the WT and mutant hMC4Rs with β-MSH as the ligand. See the legend to Fig. 2 for details. The only difference is that β-MSH was
used as the ligand instead of α-MSH.
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Table 2
β-MSH-stimulated signaling and ligand binding of WT and mutant hMC4Rs.
hMC4R n β-MSH binding β-MSH-stimulated cAMP
IC50 (nM) Bmax (% wt) EC50 (nM) Rmax (% wt)
WT 9 1506.32±272.82 100 3.24±0.59 100
I69R 3 NDa NDa NDa NDa
H76R 3 111.34±13.30b 81.74±5.94 1.18±0.29 78.40±7.29
M79I 3 632.67±221.03 98.24±10.01 283.97±149.04c 51.64±12.36
S94N 3 239.64±100.82b 40.97±12.24b 7.33±1.37b 166.81±38.56
D126Y 3 NDa NDa NDa NDa
D146N 3 66.74±31.45b 23.85±10.97b 0.47±0.18b 96.11±23.80
Del170 3 NDa NDa NDa NDa
I186V 3 1106.90±308.77 150.52±55.35 1.06±0.22b 65.81±10.68
I194T 3 NDa NDa NDa NDa
I195S 3 593.40±159.61 71.15±14.57 4.28±1.16 94.06±22.30
F201L 3 866.97±185.25 115.98±25.83 5.30±0.63b 99.95±33.34
G231V 3 1450.20±392.34 123.15±14.33 1.77±0.23b 104.94±24.02
P260Q 3 NDa NDa NDa NDa
F280L 3 536.50±188.87 57.41±23.96 1.68±0.34 129.79±24.22
I289L 3 2294.67±604.62 127.39±31.88 1.26±0.11c 76.75±24.97
L300P 3 342.63±126.95b 21.96±3.34b 5.83±1.11b 124.05±31.36
R305S 3 1327.40±421.20 128.06±27.67 6.92±1.06b 108.98±20.76
Q307X 3 NDa NDa NDa NDa
Y332C 3 832.13±140.24 129.62±18.23 1.55±0.39 93.37±19.00
Y332H 3 975.93±75.98 149.98±42.91 2.54±1.48 61.29±18.59
The data are expressed as themean±SEM of three independent experiments for themutant hMC4Rs. Themaximal responses (Rmax) were 3535.56±463.44 pmol cAMP/106 cells for
WT hMC4R.
a ND, could not be detected.
b Signiﬁcantly different from corresponding WT receptor, pb0.05.
c Signiﬁcantly different from corresponding WT receptor, pb0.01.
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Y332C, and Y332H, had decreased EC50s (Fig. 2B and Table 1).c
a
c
b a
b
c c c c
b
c c c
Fig. 4. Constitutive activities of theWTandmutanthMC4Rs. Intracellular cAMP levels in cells
transiently transfected with WT or mutant hMC4Rs were measured in the absence of any
ligand. The results are expressed as % of WT basal activity. Shown are mean±SEM of 6
experiments for the mutant hMC4Rs. The basal cAMP levels in cells expressing WT MC4R
were 36.96±4.58 pmol/106 cells (mean±SEM of 21 experiments). The statistical
signiﬁcance are indicated as follows: a: signiﬁcantly different from WT hMC4R, pb0.05;
b: signiﬁcantly different fromWThMC4R, pb0.01; c: signiﬁcantly different fromWThMC4R,
pb0.001.3.2. Ligand binding and signaling to β-MSH
Although α-MSH is usually used in MC4R studies, human genetic
studies suggest that β-MSH might also be an important endogenous
ligand, especially in humans [26,27]. We therefore also studied the
binding and signaling properties of themutant receptors using β-MSH
as the ligand.
Similar to the experiments described above for α-MSH, increasing
concentrations of unlabeled β-MSH were used to displace iodinated
NDP-MSH bound to cells expressing WT or mutant MC4Rs. These
experiments showed that unlabeled β-MSH displaced the radiola-
beled NDP-MSH with an IC50 of 1506.32 nM (Fig. 3A and Table 2).
Similar to the data whenα-MSHwas used as the ligand, four mutants,
including H76R, S94N, D146N, and L300P, had lower IC50s (increased
afﬁnities).
Stimulation with β-MSH in WT MC4R resulted in dose-dependent
increases in intracellular cAMP levels,with anEC50 of 3.24 nM(Fig. 3Band
Table 2). Data obtained from the mutants were similar to the data
obtained when α-MSH was used as the agonist, with no signaling for
I69R, D126Y, Del170, I194T, P260Q, and Q307X. M79I had decreased
maximal response and increased EC50. The other mutants could signal at
least aswell asWTMC4R in terms ofmaximal signaling. Severalmutants,
including D146N, I186V, and I289L, had decreased EC50s (Fig. 3B and
Table 2).
Since one previous study suggested that basal signaling might be
important for maintaining energy homeostasis in humans [28], we also
measured the basal signaling of the mutant MC4Rs. As shown in Fig. 4,
three mutants, H76R, D146N, and F280L, had signiﬁcantly increased
basal signaling. Of the remaining 17 mutants, 11 had decreased basal
signaling, mostly due to decreased or absent cell surface expression.
Three mutants, M79I, F201L, and R305S, had relatively normal cell
surface expression but decreased basal signaling. I186V, I195S, G231V,
I289L, Y332C, and Y332H, had normal levels of basal signaling (Fig. 4).3.3. Expression levels of the mutant receptors
Previous studies suggested that defective trafﬁcking of mutant
receptors to the cell surface is the predominant defect in naturally
occurring MC4R mutations (reviewed in [15]). To image cell surface
expression, HEK293 cells stably expressingWT ormutant receptors were
immunostained with anti-myc monoclonal antibody 9E10 and imaged
with a confocal microscope. As shown in Fig. 5A, confocal microscopy
showed that WT MC4R was expressed well on the cell surface. Some
mutants, such asM79I, D126Y, I186V, F201L, G231V, I289L, R305S, Y332C,
and Y332H, were expressed well on the cell surface. The other mutants
I69R H76R M79I D126Y
D146N Del170 I186V I194T
S94NWT
I195S F201L
G231V P260Q F280L I289L L300P R305S
Q307X Y332C Y332H
A
c
a a
c
c
c
c b
a
b c
a
a c a c 
B C
Fig. 5. Cell surface and total expression of WT and mutant hMC4Rs. A. Confocal imaging of WT and mutant hMC4Rs. TheWT or mutant myc-MC4Rs stably expressed in HEK293 cells
were stained with ﬂuorescein-conjugated anti-myc monoclonal antibody and imaged by confocal microscopy. This experiment was done twice with similar results. B. Cell surface
expression of the WT and mutant hMC4Rs was measured by ﬂow cytometry. The results are expressed as percentage of cell surface expression levels of the WT hMC4R after
correction of the nonspeciﬁc staining in cells stably transfected with the empty vector as described in Materials and methods. Data were mean±SEM of 4–5 experiments. The
statistical signiﬁcance are indicated as follows: a: signiﬁcantly different from WT hMC4R, pb0.05; b: signiﬁcantly different from WT hMC4R, pb0.01; c: signiﬁcantly different from
WT hMC4R, pb0.001. C. Total expression of the WT and mutant hMC4Rs was measured by ﬂow cytometry. The results are expressed as percentage of total expression levels of the
WT hMC4R after correction of the nonspeciﬁc staining in cells stably transfected with the empty vector as described in Materials and methods. Data were mean±SEM of 4
experiments. The statistical signiﬁcance are indicated as follows: a: signiﬁcantly different from WT hMC4R, pb0.05; c: signiﬁcantly different from WT hMC4R, pb0.001.
1196 Z.-Q. Wang, Y.-X. Tao / Biochimica et Biophysica Acta 1812 (2011) 1190–1199
Table 3
Summary of the functional properties of the twenty mutants studied herein.
MC4R Surface
expressiona
Binding Signaling Classb
Basal Stimulated
α-MSH β-MSH α-MSH β-MSH
I69R ↓ ↓ ↓ ↓ ↓ ↓ II
H76R ↓ + + ↑ + + II
M79I + + + ↓ ↓ ↓ I
S94N ↓ ↓ ↓ ↓ + + I
D126Y + ↓ ↓ ↓ ↓ ↓ III
D146N ↓ ↓ ↓ ↑ + + I
Del170 ↓ ↓ ↓ ↓ ↓ ↓ I
I186V + + + + + + V
I194T ↓ ↓ ↓ ↓ ↓ ↓ II
I195S ↓ + + + + + II
F201L + + + ↓ + + IVa
G231V + + + + + + V
P260Q ↓ ↓ ↓ ↓ ↓ ↓ II
F280L ↓ + + ↑ + + II
I289L ↑ + + + ↑ ↑ V
L300P ↓ ↓ ↓ ↓ + + II
R305S + + + ↓ + + IVa
Q307X ↓ ↓ ↓ ↓ ↓ ↓ II
Y332C + + + + + + V
Y332H + + + + + + V
+: Denotes the particular function is normal.
a Cell surface expression was quantitatively assessed by ﬂow cytometry.
b The classiﬁcation of theMC4Rmutants is based on the schemewe proposed earlier.
IVa mutants are defective only in basal signaling but not stimulated signaling.
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cell surface expression, ﬂow cytometry was used. These results showed
that 11 mutants had either absent or signiﬁcantly decreased cell surface
expression compared with WT MC4R (Fig. 5B). The expression levels of
the other mutants were not signiﬁcantly different from that of the WT
receptor (Fig. 5B).
To measure the total expression of the MC4Rs, cells were permeabi-
lized and total expression measured by ﬂow cytometry. As shown in
Fig. 5C, four mutants, including M79I, S94N, D146N, and Del170, had
signiﬁcantly decreased total expression. The other 16 mutants had
normal expression levels as the WT MC4R.
4. Discussion
In the present study, we performed detailed functional studies on 18
naturally occurringMC4Rmutations reported recently that were either
incompletely characterized or not characterized. Analogous mutations
corresponding to two mutations identiﬁed from obese mouse lines
were also characterized.We studied the pharmacology of thesemutant
receptors using both of the endogenous ligands, α- and β-MSH. Table 3
summarized the data obtained.We showed that 4mutants,M79I, S94N,
D146N, and Del170, had signiﬁcantly decreased total expression levels
as measured by ﬂow cytometry (Fig. 5C). These 4 mutants are Class I
mutants. Sixmutants, including I69R, D126Y, Del170, I194T, P260Q, and
Q307X, had little or no binding to radiolabeled ligand (Figs. 2A and 3A).
Confocal microscopy and ﬂow cytometry showed that all mutants
except D126Y had decreased or absent cell surface expression (Fig. 5A
and B). In addition to these ﬁve mutants, six additional mutants,
including H76R, S94N, D146N, I195S, F280L, and L300P, had decreased
cell surface expression (Fig. 5A and B). These 11 mutants are Class II
mutants (Table 3). We and others recently showed that small molecule
MC4R antagonists as well as some chemical chaperones could rescue
some of the intracellularly retained mutants to the cell surface and
restore function [2,25,29,30]. Whether these agents can rescue these
mutants remains to be investigated.
Aspartic acid 126 sits at the top of the third transmembrane domain.
We showed that D126Y was expressed normally at the cell surface
but no ligand binding or signaling could bemeasured. These results areconsistent with previous mutagenesis experiments demonstrating D126
as being important for binding to peptide [31] and nonpeptide [32]
ligands, hypothesized to interact with the arginine side chain of α-MSH
[33]. The corresponding Asp is also important for ligand binding in the
MC3R [24,34]. Of all the naturally occurring MC4R mutations that were
carefully characterized, only a few have been shown to be defective in
ligand binding per se [21,35,36], although some of the intracellularly
retained mutants might also be defective in ligand binding. D126Y joins
the list as a Class III mutant.
We previously reported H76R and D146N had increased basal
activities [37]. Three MC4R antagonists, including the endogenous AgRP
and two small molecule synthetic antagonists, ML00253764 and Ipsen
5i, were shown to be inverse agonists for these twomutant receptors as
well as the WT MC4R [37]. AgRP is a full inverse agonist whereas
ML00253764 and Ipsen 5i are partial inverse agonists [37]. We found
herein F280L also had increased basal activities. In addition to the
increased basal activities, the mutants had similar maximal signaling in
response toα- and β-MSH stimulation (Figs. 2B and 3B) with decreased
EC50s (Tables 1 and 2). These properties are not consistent with their
potential roles in obesity pathogenesis [38]. However, all three mutants
had decreased cell surface expression (Fig. 5), which is likely the cause
for decreased signaling in vivo, as previously suggested for L250Q [39],
another constitutively active mutant. One caveat for the in vitro
expression system is the presence of spare receptors, unlikely to occur
in vivo [15]. The reason for the decreased cell surface expression, either
due to defective forward trafﬁcking or accelerated constitutive internal-
ization/defective recycling of receptors to the cell surface resulting in
down-regulation, remains to be investigated. Defective trafﬁcking is
common innaturally occurringMC4Rmutations [14,35,40,41] (reviewed
in [42]). The MC4R is also known to undergo constitutive endocytosis
[43]. Other potential reasons for constitutively activemutants in causing
obesity are constitutive desensitization and induction of phosphodies-
terase in vivo (therefore increased cAMP degradation) as previously
observed with other constitutively active GPCR mutants [44,45].
Phosphodiesterase inhibitors are included in the in vitro experiments
described herein. Further studies are needed to clarify the mechanism
for the decreased cell surface expression of thesemutants. These studies
will be important basis for potential personalized medicine to treat
patients harboring these mutations.
The WT MC4R has some basal signaling. It was suggested that
decreased basal signaling could cause obesity [28].We showed that of the
17 mutants (excluding the three constitutively active mutants), 11 had
decreased basal signaling, mostly due to decreased or absent cell surface
expression. Only three mutants, M79I, F201L, and R305S, had relatively
normal cell surface expression but decreased basal signaling. M79I also
had decreased maximal responses to α- and β-MSH stimulation but
F201L and R305S had normalmaximal response. If indeed basal signaling
was important for energy homeostasis, F201L and R305S might cause
obesity due to defective basal signaling. Further studies are needed to
conﬁrm this hypothesis.We suggest that these threemutants are Class IV
mutants.
I194T and L300P were identiﬁed in obese mouse lines generated by
N-ethyl-N-nitrosoureamutagenesis [19]. Functional studies withmouse
MC4R showed that I194T mouse (m) MC4R has decreased cell surface
expression, ligandbinding, and increasedEC50 in response toα-MSHand
NDP-MSH stimulation, whereas L300P mMC4R has normal cell surface
expression but no ligand binding and signaling [19]. We showed here
that hMC4R I194T had decreased cell surface expression, nomeasurable
ligand binding or signaling to either α-MSH or β-MSH stimulation.
Basal signaling was also signiﬁcantly decreased. For hMC4R L300P, the
cell surface expression was decreased, with corresponding decrease
in ligand binding. However, signaling to both α-MSH and β-MSH
stimulation was similar as theWT hMC4R, although basal signaling was
signiﬁcantly decreased as compared to the WT hMC4R. These results
suggest that there are important differences in the functions of the two
conserved codons in human and mouse MC4R. The molecular basis for
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are Class IImutants. It is interesting tonote that in theMC3R,mutation in
an isoleucine residue next to the analogous position of L300 was also
found to cause intracellular retention [46,47].
Fivemutants, including I186V, G231V, I289L, Y332C, andY332H, had
normal cell surface expression, ligand binding and signaling. Therefore
they are Class V mutants, mutants with unknown defects. Whether
thesemutations are indeed the cause of obesity in individuals harboring
these mutations, and if yes, what are the molecular mechanism(s), are
not clear at present.
In summary, of the 20 mutations we studied herein, 11 (55%) had
signiﬁcantly decreased cell surface expression, consistent with previous
studies suggesting that intracellular retention is themost common defect
in naturally occurringMC4Rmutations. Many of these mutants are likely
defective in forward trafﬁcking. Decreased cell surface expression of the
three constitutively active mutants, H76R, D146N, and F280L, might be
due to defective forward trafﬁcking and/or accelerated internalization/
inefﬁcient recycling of internalized receptors. We also identiﬁedmutants
that are defective in ligand binding per se (D126Y) or signaling (M79I,
F201L, and R305S). Five mutants had normal properties compared to the
WT MC4R. Further studies are needed to identify potential therapeutic
approaches for correcting the defects of the individual mutations.
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